CL2023000580A1 - Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii - Google Patents

Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii

Info

Publication number
CL2023000580A1
CL2023000580A1 CL2023000580A CL2023000580A CL2023000580A1 CL 2023000580 A1 CL2023000580 A1 CL 2023000580A1 CL 2023000580 A CL2023000580 A CL 2023000580A CL 2023000580 A CL2023000580 A CL 2023000580A CL 2023000580 A1 CL2023000580 A1 CL 2023000580A1
Authority
CL
Chile
Prior art keywords
treatment
angiotensin
novel compounds
diseases associated
compounds
Prior art date
Application number
CL2023000580A
Other languages
English (en)
Spanish (es)
Inventor
Fex Tomas
Ohlsson Bengt
Original Assignee
Vicore Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma Ab filed Critical Vicore Pharma Ab
Publication of CL2023000580A1 publication Critical patent/CL2023000580A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2023000580A 2020-09-01 2023-02-28 Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii CL2023000580A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2013721.2A GB202013721D0 (en) 2020-09-01 2020-09-01 New compounds

Publications (1)

Publication Number Publication Date
CL2023000580A1 true CL2023000580A1 (es) 2023-10-06

Family

ID=72749608

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000580A CL2023000580A1 (es) 2020-09-01 2023-02-28 Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii

Country Status (13)

Country Link
US (1) US20230348444A1 (cg-RX-API-DMAC7.html)
EP (1) EP4208460A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023539614A (cg-RX-API-DMAC7.html)
KR (1) KR20230058467A (cg-RX-API-DMAC7.html)
CN (1) CN116568682B (cg-RX-API-DMAC7.html)
AU (1) AU2021337193A1 (cg-RX-API-DMAC7.html)
CA (1) CA3189240A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000580A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023002347A2 (cg-RX-API-DMAC7.html)
GB (1) GB202013721D0 (cg-RX-API-DMAC7.html)
IL (1) IL300582A (cg-RX-API-DMAC7.html)
MX (1) MX2023002522A (cg-RX-API-DMAC7.html)
WO (1) WO2022049372A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202104038D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
JP2024511453A (ja) * 2021-03-23 2024-03-13 ヴィコール ファルマ アーベー 選択的アンジオテンシンii受容体リガンド
GB202104033D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
WO2023193733A1 (zh) * 2022-04-06 2023-10-12 武汉人福创新药物研发中心有限公司 一种at2r激动剂
CN120569378A (zh) * 2023-01-09 2025-08-29 维科尔药物公司 选择性血管紧张素ii化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
JP4707321B2 (ja) * 2001-05-31 2011-06-22 ヴィコール・ファルマ・アーベー アンギオテンシンiiアゴニストとして有用な三環式化合物
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
AU2003302106A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
AU2006235698B2 (en) * 2005-04-12 2012-03-29 Vicore Pharma Ab New tricyclic angiotensin II agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
US20170266164A1 (en) 2014-12-12 2017-09-21 Vicore Pharma Ab New methods and uses
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
HK1244232A1 (zh) 2015-03-02 2018-08-03 维科尔药物公司 用於治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
GB201913603D0 (en) * 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds

Also Published As

Publication number Publication date
CA3189240A1 (en) 2022-03-10
GB202013721D0 (en) 2020-10-14
JP2023539614A (ja) 2023-09-15
EP4208460A1 (en) 2023-07-12
CN116568682B (zh) 2026-07-24
US20230348444A1 (en) 2023-11-02
AU2021337193A1 (en) 2023-03-23
CO2023002347A2 (es) 2023-05-19
MX2023002522A (es) 2023-03-13
JP2026126247A (ja) 2026-08-04
WO2022049372A1 (en) 2022-03-10
KR20230058467A (ko) 2023-05-03
IL300582A (en) 2023-04-01
CN116568682A (zh) 2023-08-08

Similar Documents

Publication Publication Date Title
CO2023002347A2 (es) Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii
CO2022003091A2 (es) Nuevos compuestos
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
DOP2022000172A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
UY38160A (es) Partículas implantables y métodos relacionados
CO2021005226A2 (es) Nuevos compuestos antihelmínticos
CO2018010966A2 (es) Nuevos derivados de pirazolopirimidina
MX2018014758A (es) Piridinas sustituidas con heteroarilo y metodos de uso.
CR20190212A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
ECSP13012967A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
CY1117776T1 (el) Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες
CO2024000096A2 (es) Nuevos compuestos selectivos de angiotensina ii
MX2015017865A (es) Compuestos de pirimidinodiona contra estados cardiacos.
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
UY36702A (es) Piridinas sustituidas y métodos de uso
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
NZ768368A (en) Modulators of cystic fibrosis transmembrane conductance regulator
MX2017016908A (es) Inhibidores de nadph oxidasa 4.
MX381224B (es) Potentes moduladores de gamma-secretasa.
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
MX379859B (es) Compuestos de indolinona y su uso en el tratamiento de enfermedades fibróticas.
JOP20200025A1 (ar) مركبات جديدة تنشط مسار Nrf2
MX2018008192A (es) Compuestos derivados pirimido-isoquinolin-quinonas, sus sales, isomeros, tautomeros farmaceuticamente aceptables; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de enfermedades bacterianas y bacterianas multirresistentes.
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.